![HealthTree Podcast for Multiple Myeloma artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/8f/ab/bd/8fabbdcd-0da0-0239-dac5-df547f82810a/mza_6724809222047263023.jpg/100x100bb.jpg)
Myeloma Crowd Radio: David Siegel, MD, PhD, John Theurer Cancer Center
HealthTree Podcast for Multiple Myeloma
English - May 03, 2019 19:30 - 59 minutes - 53.8 MB - ★★★★★ - 13 ratingsHealth & Fitness myeloma multiple myeloma Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
CAR T therapy is becoming a hot area of early clinical trials for multiple myeloma patients, but most are personally customized for each patient. A company called Cellectis has developed an off-the-shelf CAR T that every patient can use. Instead of being an "autologous" CAR T treatment (where you use your own cells), this is also called an "allogeneic" CAR T, or a "donor"CAR T.
Many of the current CAR T therapies are going after a target called b-cell maturation antigen (BCMA). This It is going after a different target called CS1/SLAMF7. Learn more about this new treatment (called UCARTCS1) from David Siegel, MD, PhD of Hackensack University / John Theurer Cancer Center and how it will be used in early myeloma clinical trials.
Thanks to our episode sponsor: Celgene Corporation